Immunovant, Inc.
Financial highlights
| Metric | FY 03/31/26 | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net income | -$505.6 | -$413.8 | -$259.3 | -$211.0 | -$156.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$407.3 | -$376.6 | -$214.6 | -$188.4 | -$106.4 |
Shares outstanding 206.6M · Free float 40.0%
Annual filing data through FY ended March 31, 2026; float as of September 12, 2026.